TSD statistical model - with multiple sites [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2021-10-12 11:27 (223 d 11:22 ago) – Posting: # 22625
Views: 584

Hi d_stat,

» » […] Originally we wanted to go with a variant of ‘Method C’ cause it’s slightly more powerful (esp. when you expect to stop in the IA with BE) and it is preferred by the FDA.
» Thus, we are sticking to Potvin.

I wouldn’t. It might be that the site-model mentioned above is not stable. When I tried to add ‘sites’ to Potvin’s ‘Example 2’ (subjects 1–4: 1, 5–8: 2, 9–12: 3), Phoenix/WinNonlin showed me the finger.

» In order to do the validations for multiple-site nature of the study we are thinking of amending the code in the Power2Stage, since it's not part of package yet. Am I wrong to assume the amendment will be connected to decreasing of df for the error term with the number planned sites, …

That’s correct.

» … or is there any other part that I am missing?

You would also have to modify the degrees of freedom in the function to re-estimate the sample size (sampsiz2.R).

» Of course, the alternative is always to encourage (pray to) the holy trinity to update the package ;-)

Sorry. I'm afraid your prayers will not be answered.

Maurer’s method as implemented in Power2Stage allows already to provide the degrees of freedom and the standard error of the means of a more complex model than the conventional 2×2×2 crossover.Hence, why the efforts?

Dif-tor heh smusma 🖖 [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,092 posts in 4,630 threads, 1,567 registered users;
online 10 (0 registered, 10 guests [including 4 identified bots]).
Forum time: Monday 22:49 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz